Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 2, February, p. 203–208

doi: 10.17219/acem/112604

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Serum concentration of osteopontin and interleukin 17 in psoriatic patients

Joanna Małgorzata Przepiórka-Kosińska1,A,B,C,D, Joanna Bartosińska1,A,B,C,D,E, Dorota Raczkiewicz2,B,C,D, Iwona Bojar3,C,D, Jakub Kosiński4,B,D, Dorota Krasowska1,E,F, Grażyna Chodorowska1,A,C,E,F

1 Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Poland

2 Institute of Statistics and Demography, Collegium of Economic Analysis, SGH Warsaw School of Economics, Warszawa, Poland

3 Department for Women’s Health, Institute of Rural Health, Lublin, Poland

4 Department of Rehabilitation and Orthopedics, Medical University of Lublin, Poland


Background. Psoriasis is a chronic, autoinflammatory disease characterized by activation and differentiation of naive T lymphocytes towards T helper CD4+ (including Th1 and Th17) and T cytotoxic CD8+. Osteopontin (OPN), which plays an important role in both physiological processes and inflammatory, neoplastic and autoimmune diseases, is also considered in the context of psoriasis pathogenesis. Current data indicates that OPN is a multifunctional protein involved in the modulation of Th1 and Th17 cellular responses, in stimulating keratinocyte proliferation, and in the regulation of cellular apoptosis.
Objectives. The assessment of OPN and interleukin 17 (IL-17) concentrations in the peripheral blood of psoriatic patients in comparison to healthy volunteers as well as the correlations of OPN and IL-17 with the severity of psoriasis.
Material and Methods. The study included 107 male psoriatic patients and 41 age-matched healthy men. The serum concentrations of IL-17 and OPN were examined using the enzyme-linked immunosorbent assay (ELISA) method. The skin change severity of psoriasis was assessed using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI).
Results. Psoriatic patients had significantly higher concentrations of OPN (31.65 ng/mL on average) than the healthy volunteers (11.42 ng/mL on average) (p < 0.001). Interleukin 17 was also higher in psoriatic patients (0.53 pg/mL on average) compared to healthy volunteers (0.09 pg/mL on average) (p < 0.001). There was no significant correlation between OPN and IL-17 concentrations in psoriatic patients and in healthy volunteers. Psoriasis severity correlated positively to IL-17 serum concentration, but not to OPN.
Conclusion. Although the study did not show a relationship between OPN and IL-17 concentrations in psoriatic patients, it should be emphasized that serum concentrations were significantly higher in the patients with psoriasis compared to healthy volunteers.

Key words

psoriasis, osteopontin, interleukin 17

References (30)

  1. Alwan W, Nest FO, Handale S. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl 93):2–6.
  2. Owczarczyk-Saczonek A, Placek W. Psoriasis as an autoimmune disease. Dermatology Review. 2014;101:278–287.
  3. Al-Shobaili HA, Qureshi MG. Pathophysiology of psoriasis. In: Lima H, ed. Current concepts. Psoriasis – types, causes and medication. Intech­Open London. 2013;91–105.
  4. Owczarczyk-Saczonek A, Placek W. Interleukin-17 as a factor linking the pathogenesis of psoriasis with metabolic disorders. Int J Dermatol. 2017;56(3):260–268.
  5. Hanley TL, Yiu ZZ. Role of IL-17 in plaque psoriasis: Therapeutic potential of ixekizumab. Ther Clin Risk Manag. 2017;13:315–323.
  6. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16(4):885–893.
  7. Buback F, Renkl AC, Schulz G, Weiss JM. Osteopontin and the skin: Multiple emerging roles in cutaneous biology and pathology. Exp Dermatol. 2009;18(9):750–759.
  8. Cho HJ, Cho HJ, Kim HS. Osteopontin: A multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–213.
  9. Rittling SR, Singh R. Osteopontin in immune-mediated diseases. J Dent Res. 2015;94(12):1638–1645.
  10. Ding Y, Chen J, Cui G, et al. Pathophysiological role of osteopontin and angiotensin II in atherosclerosis. Biochem Biophys Res Commun. 2016;471(1):5–9.
  11. Gürsoy G, Acar Y, Alagöz S. Osteopontin: A multifunctional molecule. JMMS. 2010;1(3):55–60.
  12. Clemente N, Raineri D, Cappellano G, et al. Osteopontin bridging innate and adaptive immunity in autoimmune diseases. J Immunol Res. 2016;2016:7675437.
  13. Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014;3(4):384–393.
  14. Sodek J, Batista Da Silva AP, Zohar R. Osteopontin and mucosal protection. J Dent Res. 2006;85(5):404–415.
  15. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol. 2008;181(11):7480–7488.
  16. Buommino E, Tufano MA, Balato N, et al. Osteopontin: A new emerging role in psoriasis. Arch Dermatol Res. 2009;301(6):397–404.
  17. Frenzel DF, Borkner L, Scheurmann J, Singh K, Scharffetter-Kochanek K, Weiss JM. Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen. Exp Dermatol. 2015;24(4):305–307.
  18. Lampe MA, Patarca R, Iregui MV, Cantor H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol. 1991;147(9):2902–2906.
  19. Chen G, Zhang X, Li R, et al. Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis. Arthritis Rheum. 2010;62(10):2900–2908.
  20. Zheng Y, Wang Z, Deng L, et al. Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells. Eur J Immunol. 2012;42(10):2803–2814.
  21. Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol. 2009;60(2):225–230.
  22. Kadry D, Hegazy RA, Rashed L. Osteopontin and adiponectin: How far are they related in the complexity of psoriasis? Arch Dermatol Res. 2013;305(10):939–944.
  23. Kadry D, Rashed R. Plasma and tissue osteopontin in relation to plasma selenium in patients with psoriasis. J Eur Acad Dermatol Venereol. 2012;26(1):66–70.
  24. Toossi P, Sadat Amini SH, Sadat Amini MS, et al. Assessment of serum levels of osteopontin, selenium and prolactin in patients with psoriasis compared with healthy controls, and their association with psoriasis severity. Clin Exp Dermatol. 2015;40(7):741–746.
  25. Abdel-Mawla MY, El-Kasheshy KA, Ghonemy S, Al Balat W, Elsayed AA. Role of osteopontin in psoriasis: An immunohistochemical study. Indian J Dermatol. 2016;61(3):301–307.
  26. Amin MM, Azim ZA. Immunohistochemical study of osteopontin, Ki-67, and CD34 of psoriasis in Mansoura, Egypt. Indian J Pathol Microbiol. 2012;55(1):56–60.
  27. El-Eishi NH, Kadry D, Hegazy RA, Rashed L. Estimation of tissue osteopontin levels before and after different traditional therapeutic modalities in psoriatic patients. J Eur Acad Dermatol Venereol. 2013;27(3):351–355.
  28. Duarte GV, Boeira V, Correia T, et al. Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity. Cytokine. 2015;74(2):287–292.
  29. Erturkler E, Cıcek D, Kaman D, Ozdogan S, Bakar Dertlioglu S. Plasma osteopontin levels in patients with Behcet’s disease and psoriasis. Eur J Dermatol. 2011;21(2):203–208.
  30. Robati RM, Partovi-Kia M, Sadat-Amini H, Haghighatkhah HR, Younespour S, Toossi P. Serum osteopontin level and common carotid artery intima-media wall thickness in psoriasis. Int J Dermatol. 2016;55(5):262–267.